Add to a list

Inactive Instrument

ViaDerma, Inc. Stock Other OTC

VDRM

US92555K1016

Biotechnology & Medical Research

on all subscriptions*

Exceptional extension!

Enjoy this offer

* See conditions under "Our services"

ViaDerma, Inc. is a pharmaceutical company. The Company is engaged in the manufacture and sale of pharmaceutical related products in the United States of America. The Companyâ€™s lead product is a topical antibiotic, which is focused on being sold under the brand name Vitastem. The Company also has products in development in the fields: anti-aging skin care, pain management, hair-loss, and toenail fungus. Its products are based on a patent-pending delivery system technology that allows for rapid mass transfer of the pharmaceutical active ingredient across the skin and into the body to provide immediate localized therapy. The Company utilizes a specific trade secret formulation system in the manufacture of all products. The Companyâ€™s products are sold to local medical practitioners and patients in clinics primarily in the Los Angeles, California area. The Companyâ€™s subsidiary is ViaDerma, II Inc.

Employees

Sector

Biotechnology & Medical Research

More about the company

-40%: Exceptional extension

SEIZE THE OFFER!

Market Cap	6.31M 5.5M 5.09M 4.77M 8.94M 595M 8.99M 60.41M 23.41M 293M 23.67M 23.16M 1.02B	P/E 2015	10.7x	P/E 2016	-3.3x
Enterprise Value	6.6M 5.76M 5.33M 4.99M 9.36M 623M 9.42M 63.25M 24.51M 307M 24.78M 24.25M 1.06B	EV / Sales 2015	1.5x	EV / Sales 2016	3.63x
Free-Float	99%	Yield 2015 *	-	Yield 2016	-

21/01/25	ViaDerma, Inc. Strengthens Global Expansion with New Dubai Office and Progress Towards Product Registration in India	CI
13/08/24	ViaDerma, Inc. Announces Commencement of the Registration Process in Kenya, Namibia, and Tanzania for Strategic Expansion into East and Southern Africa	CI
13/08/24	ViaDerma, Inc. Announces Shipment of 500,000 Units of its Product to Nigeria	CI
01/08/24	ViaDerma, Inc. Finalizes Distribution Agreements in Dubai	CI
16/03/23	ViaDerma, Inc. Announces FDA Registration Application Update & Brand Name for New Hair Regrowth Product	CI
08/03/23	ViaDerma Announces Intent to Launch New Minoxidil Hair Regrowth Product	CI
15/09/22	ViaDerma, Inc. Successfully Completes Quality Control Testing of Its New Vitastem Products	CI
04/10/21	ViaDerma, Inc. Set to Launch Two New and Improved Versions of Its Flagship Product, Vitastem and Vitastem Ultra	CI
24/06/21	ViaDerma, Inc. Provides Updates on Current Business Activities	CI
02/06/21	ViaDerma, Inc. Announces Expansion of Its Current Licensing Agreement	CI
13/05/21	ViaDerma, Inc. Nearing Initial Order from Large Hospital Network	CI
08/04/21	ViaDerma, Inc. Provides Revenue Guidance for the First Quarter of 2021	CI
21/01/21	ViaDerma, Inc. Completes a Licensing Agreement with a Group of Affiliate Wound Care Medical Practices Operating in Six States	CI

16/07/25	ViaDerma Announces Posting of Annual Report and Ongoing Evaluation of Public Status in Response to Market Changes	AQ
04/06/25	ViaDerma, Inc. Confirms Ongoing Operations and Commitment to Regulatory Compliance	AQ
21/01/25	ViaDerma, Inc. Strengthens Global Expansion with New Dubai Office and Progress Towards Product Registration in India	AQ
10/12/24	ViaDerma Announces Significant 2024 Achievements and International Expansion	AQ
03/10/24	ViaDerma, Inc. Reports Strong Financial Results for Q2 2024, Achieving Positive Net Income and Significant Cash Flow Growth	AQ

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
VIADERMA, INC.	+5.85%	-24.07%	-	-	493K
LONZA GROUP AG	+0.60%	+1.05%	-10.84%	-5.09%	43.13B
REVOLUTION MEDICINES, INC.	+0.96%	+2.23%	+308.65%	+555.29%	34.65B
BEONE MEDICINES AG	+0.79%	+1.09%	+5.29%	+45.84%	30.03B
IQVIA HOLDINGS INC.	-2.24%	-8.25%	+5.48%	-23.38%	28B
CELLTRION, INC.	-1.06%	-2.60%	+9.08%	+21.51%	24.45B
ASCENDIS PHARMA A/S	+0.55%	+3.47%	-	-	14.34B
MEDPACE HOLDINGS, INC.	-2.81%	-4.71%	+44.33%	+98.34%	13.14B
EUROFINS SCIENTIFIC SE	+0.74%	-0.60%	+5.85%	+8.06%	12.53B
IONIS PHARMACEUTICALS, INC.	+1.25%	+0.75%	+97.81%	+80.86%	12.25B
Average	+0.45%	+0.65%	+58.21%	+97.68%	23.61B
Weighted average by Cap.	-0.07%	+1.19%	+63.66%	+114.30%

	2015	2016
Net sales	192K 167K 155K 145K 272K 18.1M 274K 1.84M 712K 8.91M 720K 704K 30.93M	252K 220K 203K 190K 357K 23.78M 359K 2.41M 936K 11.7M 946K 926K 40.64M
Net income	27.12K 23.65K 21.9K 20.5K 38.45K 2.56M 38.68K 260K 101K 1.26M 102K 99.62K 4.37M	-122K -106K -98.36K -92.08K -173K -11.49M -174K -1.17M -452K -5.66M -457K -447K -19.64M
Net Debt	288K 251K 233K 218K 409K 27.2M 411K 2.76M 1.07M 13.39M 1.08M 1.06M 46.48M	297K 259K 240K 224K 421K 28M 423K 2.84M 1.1M 13.78M 1.11M 1.09M 47.86M

ViaDerma, Inc. Stock Other OTC

Stocks

VDRM

US92555K1016

Biotechnology & Medical Research

Valuation: ViaDerma, Inc.

Latest news : ViaDerma, Inc.

Press Releases: ViaDerma, Inc.

Quotes and Performance

Managers and Directors: ViaDerma, Inc.

Other Biotechnology & Medical Research

Financials

Company Profile